↓ Skip to main content

Aging

The potential benefit of metformin to reduce delirium risk and mortality: a retrospective cohort study

Overview of attention for article published in Aging, November 2022
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (97th percentile)
  • High Attention Score compared to outputs of the same age and source (88th percentile)

Mentioned by

news
7 news outlets
blogs
2 blogs
twitter
18 X users
facebook
1 Facebook page
reddit
1 Redditor
video
1 YouTube creator

Citations

dimensions_citation
5 Dimensions

Readers on

mendeley
9 Mendeley
Title
The potential benefit of metformin to reduce delirium risk and mortality: a retrospective cohort study
Published in
Aging, November 2022
DOI 10.18632/aging.204393
Pubmed ID
Authors

Takehiko Yamanashi, Zoe-Ella Em Anderson, Manisha Modukuri, Gloria Chang, Tammy Tran, Pedro S Marra, Nadia E Wahba, Kaitlyn J Crutchley, Eleanor J Sullivan, Sydney S Jellison, Katie R Comp, Cade C Akers, Alissa A Meyer, Sangil Lee, Masaaki Iwata, Hyunkeun R Cho, Eri Shinozaki, Gen Shinozaki

Abstract

Metformin has been reported to improve age-related disorders, including dementia, and to lower mortality. This study was conducted to investigate whether metformin use lower delirium risk, as well as long-term mortality. In this retrospective cohort study, previously recruited 1,404 subjects were analyzed. The relationship between metformin use and delirium, and the relationship between metformin use and 3-year mortality were investigated. 242 subjects were categorized into a type 2 diabetes mellitus (DM)-without-metformin group, and 264 subjects were categorized into a DM-with-metformin group. Prevalence of delirium was 36.0% in the DM-without-metformin group, and 29.2% in the DM-with-metformin group. A history of metformin use reduced the risk of delirium in patients with DM (OR, 0.50 [95% CI, 0.32 to 0.79]) after controlling for confounding factors. The 3-year mortality in the DM-without-metformin group (survival rate, 0.595 [95% CI, 0.512 to 0.669]) was higher than in the DM-with-metformin group (survival rate, 0.695 [95% CI, 0.604 to 0.770]) (p=0.035). A history of metformin use decreased the risk of 3-year mortality after adjustment for confounding factors (HR, 0.69 [95% CI, 0.48 to 0.98]). Metformin use may lower the risk of delirium and mortality in DM patients.

X Demographics

X Demographics

The data shown below were collected from the profiles of 18 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 9 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 9 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 1 11%
Other 1 11%
Student > Master 1 11%
Unknown 6 67%
Readers by discipline Count As %
Medicine and Dentistry 2 22%
Business, Management and Accounting 1 11%
Pharmacology, Toxicology and Pharmaceutical Science 1 11%
Unknown 5 56%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 74. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 March 2023.
All research outputs
#569,049
of 25,235,161 outputs
Outputs from Aging
#151
of 4,086 outputs
Outputs of similar age
#13,713
of 491,476 outputs
Outputs of similar age from Aging
#11
of 86 outputs
Altmetric has tracked 25,235,161 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,086 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 12.8. This one has done particularly well, scoring higher than 96% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 491,476 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 86 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 88% of its contemporaries.